BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22744210)

  • 21. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer.
    Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S
    PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.
    Bouquet F; Pal A; Pilones KA; Demaria S; Hann B; Akhurst RJ; Babb JS; Lonning SM; DeWyngaert JK; Formenti SC; Barcellos-Hoff MH
    Clin Cancer Res; 2011 Nov; 17(21):6754-65. PubMed ID: 22028490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
    Oh E; Hong J; Kwon OJ; Yun CO
    Sci Rep; 2018 Jan; 8(1):1420. PubMed ID: 29362367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.
    Futakuchi M; Nannuru KC; Varney ML; Sadanandam A; Nakao K; Asai K; Shirai T; Sato SY; Singh RK
    Cancer Sci; 2009 Jan; 100(1):71-81. PubMed ID: 19038005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular imaging of TGFβ-induced Smad2/3 phosphorylation reveals a role for receptor tyrosine kinases in modulating TGFβ signaling.
    Nyati S; Schinske K; Ray D; Nyati MK; Ross BD; Rehemtulla A
    Clin Cancer Res; 2011 Dec; 17(23):7424-39. PubMed ID: 21948232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
    Huch M; Gros A; José A; González JR; Alemany R; Fillat C
    Neoplasia; 2009 Jun; 11(6):518-28, 4 p following 528. PubMed ID: 19484141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
    Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
    Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
    Mourskaia AA; Dong Z; Ng S; Banville M; Zwaagstra JC; O'Connor-McCourt MD; Siegel PM
    Oncogene; 2009 Feb; 28(7):1005-15. PubMed ID: 19079339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
    Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL
    J Clin Invest; 2002 Jun; 109(12):1551-9. PubMed ID: 12070302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
    Zhao H; Wang H; Kong F; Xu W; Wang T; Xiao F; Wang L; Huang D; Seth P; Yang Y; Wang H
    Hum Gene Ther; 2019 Feb; 30(2):197-210. PubMed ID: 30032645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
    Wendt MK; Schiemann WP
    Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth.
    Hsiao WC; Sung SY; Liao CH; Wu HC; Hsieh CL
    Mol Pharm; 2012 May; 9(5):1396-408. PubMed ID: 22480282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Construction of recombinant adenovirus vector expressing extracellular domain of TbetaR-II-RANTES fusion gene and its anti-tumor effects].
    Wang XD; Liu H; Cao S; Li H; Ren XB; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):405-10. PubMed ID: 17974270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
    Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
    Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
    Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K
    Br J Cancer; 2010 Mar; 102(5):844-51. PubMed ID: 20145621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.